[1]Jager NG, Linn SC, Schellens JH, et al. Tailored tamoxifen treatment for breast cancer patients: A perspective[J]. Clin Breast Cancer, 2015,15(4):241-244.
[2]van Hasselt JG, van Eijkelenburg NK, Beijnen JH, et al. Optimizing drug development of anti-cancer drugs in children using modelling and simulation[J]. Br J Clin Pharmacol, 2012, 76(1):30-47.
[3]Peck R. Precision medicine is not just genomics: The right dose for every patient[J]. Annu Rev Pharmacol Toxicol, 2018, 58(8):1-18.
[4]Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future[J]. Clin Pharmacol Thera, 2017,101(5):646-656.
[5]Gonzalez D, Rao GG, Bailey SC, et al. Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact[J]. Clin Transl Sci, 2017,10:443-454.
[6]Swain SM, Kim S, Cortes J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2013, 14:461-471.
[7]von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377:122-131.
[8]Fletcher CD, Bridge JA, Hogendoorn P, et al. WHO classification of tumours of soft tissue and bone[M].4th ed. // IARC: WHO classification of tumours, volume 5.
[9]Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer Version 2.2015[J]. J Natl Compr Canc Netw, 2015, 13(4):448-475.
[10]Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer Version 3.2019[EB/OL]. (2019-09-06)[2019-09-27].https://www.nccn.org/patients/default.aspx.
[11]Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis[J]. Pharm Res, 2006, 23(6):1275-1284.
[12]Garg A, Quartino A, Li J, et al. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors[J]. Cancer Chemother Pharmacol, 2014, 74:819-829.
[13]Bruno R, Washington CB, Lu J, et al. Population pharmacokinetics of trastuzumab in patients with HER2+metastatic breast cancer[J]. Cancer Chemother Pharmacol, 2005, 56:361-369.
[14]Quartino AL, Hillenbach C, Li J, et al. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer[J]. Cancer Chemother Pharmacol, 2016,77:77-78.
[15]Charoin JE, Jacqmin P, Banken L, et al. Population pharmacokinetic analysis of trastuzumab(Herceptin) following long-term administration using different regimens[R/OL]. https://www.page-meeting.org/page/page2004/PAGE2004P33.pdf
[16]Fukushima Y,Charoin JE, Brewster M, et al. Population pharmacokinetic analysis of trastuzumab(Herceptin) based on data from three different dosing regimens[R/OL]. https://www.page-meeting.org/pdf_assets/5916-2007_PAGE_Herceptin.pdf.
[17]Washington GB, Lieberman G, Liu P, et al. A population pharmacokinetic model for trastuzumab following weekly dosing[J]. Clin Pharmacol Ther, 2002, 71(2): 12.
[18]Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab[J]. CPT Pharmacometrics Syst Pharmacol, 2014, 3:e87.
[19]Waldmann TA, Strober W. Metabolism of immunoglobulins[J]. Prog Allergy,1969,13:1-110.
[20]Du Bois D, Du Bois EF. Clinical calorimetry: Tenth paper, a formula to estimate the approximate surface area if height and weight be known[J]. JAMA Int Med, 1916, XVII(6.2):863-871.
[21]Hallynck TH, Soep HH, Thomis JA, et al. Should clearance be normalised to body surface or to lean body mass[J]? Br J Clin Pharmacol, 1981,11(5):523-526.
[22]Malik MA, Totpal K, Balter I, et al. Dose-response studies of recombinant humanized monoclonal antibody 2c4 in tumor xenograft models[J]. Proc Am Soc Cancer Res, 2003, 44:176-177.
[23]Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers[J]. Oncogene, 1999, 18:2241-2251.
[24]Swain SM, Im YH, Im SA,et al.Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA[J]. The Oncologist, 2014,19:693-701.
[25] Keefe DL. Trastuzumab-associated cardiotoxicity[J]. Cancer, 2002, 95(7):1592-1600. |